


Advanced Delivery and Therapeutic Applications of **RNAi**

Editors

Kun Cheng

Ram I. Mahato



WILEY

Advanced Delivery and Therapeutic Applications of RNAi

Edited by


KUN CHENG

*School of Pharmacy, University of
Missouri-Kansas City, USA*

and

RAM U. MAHAJAN

*Department of Pharmaceutical Sciences,
University of Tennessee Health Science
Center, USA*



WILEY

This edition first published 2013
© 2013 John Wiley and Sons Ltd

Registered office

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com.

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data applied for.

A catalogue record for this book is available from the British Library.

ISBN: 9781119976868 (13 digits)

Set in 10/12pt, Times by Thomson Digital, Noida, India.

Printed and bound in Singapore by Markono Print Media Pte Ltd

Advanced Delivery and Therapeutic Applications of RNAi

I dedicate this book to my parents, Mr. Guangxiong Cheng and Mrs. Pingqing Xu, my wife Lizhi Sun, my children Daniel and Jessica for their love and continuous support, and to my mentors who have inspired me to pursue a career in science.

Kun Cheng

I dedicate this book to my wife Subhashini, my children Kalika and Vivek for their love and support; my late mother Sarswati for believing in me; and to my students and mentors who have always helped me in my quest for learning and in achieving higher goals.

Ram I. Mahato

Preface

RNA interference (RNAi) is one of the most dramatic findings since the beginning of the twenty-first century, and remarkable progress has been made in different aspects of the RNAi technology since its discovery in 1998. Generally, RNAi can be achieved by three strategies: chemical synthesized small interfering RNA (siRNA), long double-stranded RNA (dsRNA), and DNA-based (plasmid or viral vector) short hairpin RNA (shRNA). The versatility and specificity of RNAi have quickly evolved the technology from a powerful tool for studying the genetic function of a specific gene to a promising therapeutic paradigm for a variety of diseases. However, the field of RNAi therapy has a frustrating history that is similar to that of other nucleic acid-based therapies. Poor stability and cellular uptake are the two major limitations for the successful application of RNAi therapy. Since 2011, several major investors in RNAi technology have announced that they would close down their RNAi research after spending hundreds of millions of dollars in the past few years. Lack of an efficient delivery system for RNAi to overcome numerous biological obstacles *in vivo* is believed to be the major reason for these tough decisions. At the time of writing, there were 22 ongoing or completed clinical trials using RNAi for numerous diseases. The majority of these clinical trials employed naked siRNA for local treatment of ocular or respiratory diseases. This actually indicates *delivery* as the single most important challenge faced by siRNA therapeutics. All these facts clearly indicate that *efficient delivery* is the crucial step in transforming RNAi molecules from groundbreaking scientific discovery to successful therapeutics.

Advanced Delivery and Therapeutic Applications of RNAi aims to provide up-to-date information about the basics, delivery and therapeutic applications of RNAi. The book is divided into three parts, starting with fundamentals related to mechanisms, biological barriers, analysis, and regulatory perspectives of RNAi. Part II, on RNAi delivery strategies, discusses different strategies for RNAi delivery and targeting. The book ends with the current applications of RNAi for various diseases including cancer, liver disease, and ocular disease. The book presents a wide variety of aspects of the development of RNAi therapeutics from bench to clinic, which have not yet been addressed in a single book. We hope that this book will serve as a useful tool for scientists who are interested in exploring the therapeutic potential of RNAi technology.

We would like to express our sincere appreciation and gratitude to all contributors who have made time to share their knowledge, experience and expertise in different aspects of RNAi. We would also like to thank Paul Deards, Sarah Tilley, Jasmine Kao, and Emma Strickland at Wiley for their help in the planning, preparation and production of this book.

Contributors

Patrick Arbuthnot, Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, South Africa

Gabriel Lopez-Berestein, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA

Paul Brown, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Arturo Chavez-Reyes, Centro de Investigación y de Estudios Avanzados del IPN, México

Kun Cheng, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri – Kansas City, USA

Carol Crowther, Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, South Africa

Sally-Ann Cryan, School of Pharmacy, Royal College of Surgeons in Ireland, Ireland

Rolf Dermietzel, Department of Neuroanatomy and Molecular Brain Research, Ruhr-University Bochum, Germany

Robert T. Dorsam, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Abdullah Ely, Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, South Africa

Sara Ferrando-Martínez, Laboratorio Inmunobiología Molecular y Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Spain

Lance Ford, Bioo Scientific Corp., USA

Simon H. Friedman, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, USA

Jose Luis Jiménez Fuentes, Laboratorio Inmunobiología Molecular y Plataforma de Laboratorio. Hospital General Universitario Gregorio Marañón, Spain

Xiang Gao, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Mohammed Ghazwani, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Rafael Gómez, Dpto. de Química Inorgánica, Universidad de Alcalá, Spain

Catherine M. Greene, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Ireland

K. Jeyaseelan, Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore

Wei Jin, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri – Kansas City, USA

D.S. Karolina, Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore

Ciara Kelly, School of Pharmacy, Royal College of Surgeons in Ireland, Ireland

China Malakondaiah Kummitha, Biomedical Engineering, Case Western Reserve University, USA

Manuel Leal, Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine of Seville, IBiS, Virgen del Rocio University Hospital/CSiC/University of Seville, Spain

Shwu-Luan Lee, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Feng Li, School of Pharmacy, Hampton University, USA and Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, USA

Jiang Li, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Song Li, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Jiakai Lin, Institute of Bioengineering and Nanotechnology, Singapore

Jianqin Lu, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Zheng-Rong Lu, Biomedical Engineering, Case Western Reserve University, USA

Ram I. Mahato, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, USA

Wilson X. Mai, Division of NanoMedicine, Department of Medicine, University of California, USA

Anthony S. Malamas, Biomedical Engineering, Case Western Reserve University, USA

Fredric P. Manfredsson, Department of Translational Science and Molecular Medicine, Michigan State University, USA

Javier de la Mata, Dpto. de Química Inorgánica, Universidad de Alcalá, Spain

Paul J. McKiernan, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Ireland

Huan Meng, Division of NanoMedicine, Department of Medicine, University of California, USA

Mohube Betty Mowa, Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, South Africa

M^aAngeles Muñoz-Fernandez, Laboratorio Inmunobiología Molecular y Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Spain

Yukio Nagasaki, Department of Materials Science, Graduate School of Pure and Applied Sciences, University of Tsukuba, Japan

Paula Ortega, Dpto. de Química Inorgánica, Universidad de Alcalá, Spain

Yi Pei, Department of RNA Therapeutics, Merck Research Laboratories, USA

Bin Qin, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri – Kansas City, USA

Cristian Rodriguez-Aguayo, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, USA

John J. Rossi, Molecular and Cellular Biology, Beckman Research Institute of City of Hope, USA

Anil K. Sood, Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, USA

Sandesh Subramanya, Bioo Scientific Corp., USA

Atsushi Tamura, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Japan

Andrey Turchinovich, Department of Neuroanatomy and Molecular Brain Research, Ruhr-University Bochum, Germany

Jian Wang, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Shu Wang, Institute of Bioengineering and Nanotechnology, Singapore and Department of Biological Sciences, National University of Singapore, Singapore

Tian Xia, Division of NanoMedicine, Department of Medicine, University of California, USA

Awadh B. Yadav, School of Pharmacy, Royal College of Surgeons in Ireland, Ireland

Chae-Ok Yun, Department of Bioengineering, College of Engineering, Hanyang University, Seoul Korea

Peng Zhang, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Yifei Zhang, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, USA

Jiehua Zhou, Molecular and Cellular Biology, Beckman Research Institute of City of Hope, USA

Georg Zoidl, Department of Neuroanatomy and Molecular Brain Research, Ruhr-University Bochum, Germany

About the Editors

Kun Cheng is a Principal Investigator in Pharmaceutical Sciences at the University of Missouri Kansas City (UMKC). Dr Cheng received his BS and MS in pharmaceutical sciences from China Pharmaceutical University. He also received a MS in pharmacy from the National University of Singapore. He worked at Bright Future Pharmaceutical Company in Hong Kong prior to joining the University of Tennessee Health Science Center, where he received his PhD in pharmaceutical sciences. His current research focuses on the development of novel drug delivery systems for siRNA and small-molecule drugs. He is the recipient of the 2011 American Association of Pharmaceutical Scientists (AAPS) New Investigator Grant Award in Pharmaceutics and Pharmaceutical Technology. He has been actively engaged in extramural professional activities and teaching graduate and PharmD courses. He has edited two theme issues for *Molecular Pharmaceutics* and *Pharmaceutical Research*.

Ram I. Mahato is a full time Professor of Pharmaceutics and Drug Delivery at the Department of Pharmaceutical Sciences, University of Tennessee Health Science Centre, Memphis. Dr Mahato has served as a Research Assistant Professor at the University of Utah, as Senior Scientist at GeneMedicine, Inc., and as a postdoctoral fellow at the University of Southern California, Washington University and Kyoto University. He received a PhD in pharmaceutics and drug delivery from the University of Strathclyde (Glasgow) in 1992. He has two issued United States patents and is author or co-author of more than 105 papers and book chapters. He has edited nine journal theme issues, and six books, and has written one textbook. He is a theme issue editor for *Pharmaceutical Research* and a member of the editorial board of eight journals. He is an AAPS and CRS Fellow and regular member of the BTSS Study section of the National Institutes of Health. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA and genes.

Contents

<i>Preface</i>	xvii
<i>Contributors</i>	xix
<i>About the Editors</i>	xxiii
Part 1 Introduction and Basics of RNAi	1
1 Mechanisms and Barriers to RNAi Delivery	3
<i>Jiehua Zhou and John J. Rossi</i>	
1.1 Introduction	3
1.2 Barriers to Systemic RNAi Delivery	5
1.3 Rational Design to Improve RNAi Efficacy	6
1.4 Chemical Modifications to Enhance siRNA Stability and Reduce Immune Response	7
1.5 Cellular Uptake and Intracellular Release of siRNA	7
1.6 Combinatorial Targeting for Targeted RNAi Delivery	8
1.7 Cell-Specific Aptamer-Functionalized Nanocarriers for RNAi Delivery	9
1.8 The Clinical Development and Challenges of siRNAs Therapeutics	10
1.9 Conclusion and Perspectives	12
References	12
2 Analysis of siRNA Delivery Using Various Methodologies	19
<i>Yi Pei</i>	
2.1 Introduction	19
2.2 Checkpoints for Analyzing siRNA Delivery	20
2.2.1 Circulation Checkpoint	22
2.2.2 Organ or Tissue Checkpoint	22
2.2.3 Cellular Checkpoint	22
2.2.4 RISC Checkpoint	23
2.2.5 Target mRNA Knockdown (Indirect Checkpoint)	24
2.2.6 Protein and Outcome (Indirect Checkpoint)	25
2.2.7 Safety (Indirect Checkpoint)	26
2.3 Methods for Analysis of siRNA	26
2.3.1 General Considerations	26
2.3.2 Hybridization-Based (Non-Imaging) Methods	28
2.3.3 Non-Hybridization-Based (Non-Imaging) Methods	34
2.3.4 Imaging-Based (Non-Hybridization) Methods	35
2.3.5 Imaging-Based (Hybridization) Methods	37

2.4	Case Study for siRNA Delivery Analysis	38
	References	39
3	Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed	45
	<i>Sandesh Subramanya and Lance Ford</i>	
3.1	Introduction	45
3.2	RNAi Mediator (siRNA or shRNA)	45
3.2.1	siRNA	45
3.2.2	Vector-derived shRNA	47
3.2.3	miRNAs	49
3.3	Safety Issues of RNAi Mediators	50
3.3.1	Immune Stimulation	50
3.3.2	RNAi Overexpression	52
3.4	Efficacy of RNAi Mediators	52
3.4.1	Therapeutic Response	52
3.5	RNAi Mediators in Clinical Trials	53
3.6	Conclusion	54
	References	55
4	Nonclinical Safety Assessments and Clinical Pharmacokinetics for Oligonucleotide Therapeutics: A Regulatory Perspective	63
	<i>Shwu-Luan Lee, Paul Brown, Jian Wang and Robert T. Dorsam</i>	
4.1	Introduction	63
4.2	Unique Properties of Oligonucleotide-based Therapeutics	63
4.3	Regulation of Oligonucleotide-Based Therapeutics	65
4.3.1	Submission to the FDA	65
4.3.2	Review Process for Non-clinical Studies	67
4.3.3	Regulatory Issues	74
4.3.4	Clinical Pharmacokinetics	76
4.4	Conclusion	79
	Disclaimer	79
	Appendix	79
	References	80
5	Role of Promoters and MicroRNA Backbone for Efficient Gene Silencing	83
	<i>Feng Li and Ram I. Mahato</i>	
5.1	Introduction	83
5.2	Promoters for shRNA Expression	84
5.2.1	Constitutive Promoters	84
5.2.2	Inducible Promoters	87
5.2.3	Site Specific Promoters	93
5.3	miRNA-based shRNAs	96